Skip to Content Skip to Search
Group of people discussing over an open laptop

GSK in Canada

GSK has a history in Canada that dates back to 1902

We currently employ approximately 2,600 full time employees across the country, providing a salary injection of $295 million into the Canadian economy. We have two divisional headquarters in Mississauga, Ontario and Laval, Quebec, and an administrative office in Quebec City.


Our two manufacturing facilities are located in:

Ste-Foy - Quebec

The Ste-Foy vaccine manufacturing site currently produces a majority share of Canada’s seasonal influenza vaccine and is responsible for the domestic supply of the country’s pandemic influenza vaccine requirements.

Ville Saint-Laurent - Quebec

The Ville Saint-Laurent site produces consumer products such as Advil, Centrum, Robitussin, Robax and Caltrate among others.

Research & Development

We have invested more than $2 billion since 2001 in Canadian pharmaceutical and vaccines Research & Development (R&D), with 60 million in 2020 alone. In 2020, we invested over $9.1 million into 32 active clinical trials across Canada involving 1,303 active subjects.

Community Investment

  • Over $1,200,000

    Invested in grants and donations to community groups by GSK in Canada in 2019

  • Over $3,000,000

    Contributed over the last 20 years to support the hospice palliative care movement in Canada. In 2019 only, we contributed $200,000 to help ensure every Canadian has access to quality hospice palliative care.

  • More than 7,500

    Emergency backpacks delivered to children in Ontario and Manitoba since 2016 by GSK and Save the Children—helping to support Indigenous children, families and communities to prepare for climate-related disasters.

Environmental Sustainability

In October 2018, GSK launched a Centralized Waste program involving the removal of individual waste containers from offices to promote environmental consciousness and reduce our contribution to landfills.

In November 2020, GSK announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030.

Learn more about our commitment to the environment


Our Response

  • We are collaborating with companies and research groups across the world—working on COVID-19 vaccine candidates through the use of our pandemic adjuvant technology.
  • We do not expect to profit from COVID-19 vaccines during the pandemic phase, and will invest any short-term profit in coronavirus related research and long-term pandemic preparedness.
  • GSK Canada has contributed over $750,000 in corporate grants in support of COVID-19 relief efforts

Ways of Working

GSK is committed to building transparency in our operations because it enhances trust and value for patients and our healthcare system.

Since 2017, GSK has been among ten leading pharmaceutical companies in Canada that have voluntarily disclosed aggregate payments to healthcare providers (HCPs) and healthcare organizations. Starting in 2020 and onwards, we are disclosing individual level payments made annually to HCPs.

Learn more about our commitment to transparency